CAR T-cell therapy for multiple myeloma shows no difference in survival outcomes by race and ethnicity

Patients with multiple myeloma treated with idecabtagene vicleucel, known as “ide-cel,” a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according to a study published in Blood Advances.

Newcourt Acquisition Corp Announces Continuation of Business Combination Close Process | Psychedelic Invest

Newcourt Acquisition Corp (“Newcourt”) (NASDAQ: NCAC) announced today that the conditions to closing the business combination (the “Business Combination”) pursuant to the Amended and Restated Business

January 23, 2024

Uncommon genetic allele variants may play a vital role in treatment-resistant depression, finds study

The association between treatment-resistant depression and uncommon functional genetic alleles.

August 3, 2023

Coherus sells Sandoz its Lucentis biosimilar for $170M to focus on oncology assets

Coherus BioSciences is selling its FDA-approved ophthalmology biosimilar Cimerli — a copycat version of Roche’s Lucentis — to Sandoz for $170 million in cash to

January 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.